Get a deeper insight into the potential performance of Pfizer (PFE) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of ...

March 17 (Reuters) - Pfizer (PFE.N), opens new tab said on Tuesday its experimental combination reduced the risk of disease progression or death by 40% in patients with breast cancer. Here are some ...

Pfizer’s revenue reached $100 billion a few years ago, driven by its dominance in coronavirus treatments and prevention. In recent times, it’s faced a drop in that demand and losses of exclusivity ...

Oct 18 (Reuters) - Pfizer (PFE.N), opens new tab and Japanese firm Astellas' (4503.T), opens new tab drug Padcev, combined with Merck's (MRK.N), opens new tab Keytruda, lowered the risk of tumor ...

Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...

Pfizer (NYSE:PFE) received U.S. FDA Priority Review for a supplemental Biologics License Application covering PADCEV plus ...

Boston-based Akili Interactive Labs and Pfizer have released data from a collaborative study showing the use of Akili’s digital, cognitive measurement platform can detect biomarkers of Alzheimer’s ...

Promising clinical results in 2026 could set the stage for Pfizer's stock to rebound. However, the company's COVID-19 product and patent cliff challenges could prevent a big bounce this year. Even if ...

Matthew Herper covers medical innovation — both its promise and its perils. An experimental vaccine from Pfizer and Valneva reduced the risk of developing Lyme disease by more than 70%, according to ...

Add Yahoo as a preferred source to see more of our stories on Google. President Donald Trump today, Sept. 30, announced TrumpRX, a new website for Americans to buy drugs, while he touted lower prices ...